EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

Emily Gruber, Lev M Kats iD

Biochemical Society Transactions · 31.08.2023 · 51 (4) · 1675-1686

DOI: 10.1042/bst20230017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 01.08.2023. Verfasst von Emily Gruber und 1 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Of the many genetic alterations that occur in cancer, relatively few have proven to be suitable for the development of targeted therapies. Mutations in isocitrate dehydrogenase (IDH) 1 and -2 increase the capacity of cancer cells to produce a normally scarce metabolite, D-2-hydroxyglutarate (2-HG), by several orders of magnitude. The discovery of the unusual biochemistry of IDH mutations spurred a flurry of activity that revealed 2-HG as an ‘oncometabolite’ with pleiotropic effects in malignant cells and consequences for anti-tumour immunity. Over the next decade, we learned that 2-HG dysregulates a wide array of molecular pathways, among them a large family of dioxygenases that utilise the closely related metabolite α-ketoglutarate (α-KG) as an essential co-substrate. 2-HG not only contributes to malignant transformation, but some cancer cells become addicted to it and sensitive to inhibitors that block its synthesis. Moreover, high 2-HG levels and loss of wild-type IDH1 or IDH2 activity gives rise to synthetic lethal vulnerabilities. Herein, we review the biology of IDH mutations with a particular focus on acute myeloid leukaemia (AML), an aggressive disease where selective targeting of IDH-mutant cells is showing significant promise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansMutationKetoglutaric AcidsCell Transformation, NeoplasticIsocitrate Dehydrogenase

Stichwörter der Autor:innen

2-HGIDH mutationacute myeloid leukaemiatargeted therapies

Substanzen

Ketoglutaric AcidsIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia.

ORCID-Profile: Lev M Kats

Zitieren

APA

Gruber, E., & Kats, L. M. (2023). The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches. Biochemical Society Transactions, 51(4), 1675-1686. https://doi.org/10.1042/bst20230017

Vancouver

Gruber E, Kats LM. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches. Biochemical Society Transactions. 2023;51(4):1675-1686. doi:10.1042/bst20230017

BibTeX
@article{Gruber2023,
  author = {Gruber, Emily and Kats, Lev M},
  title = {The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches},
  journal = {Biochemical Society Transactions},
  year = {2023},
  volume = {51},
  number = {4},
  pages = {1675--1686},
  doi = {10.1042/bst20230017}
}
Kostenlos starten →